FDA Clears First Targeted Dermatomyositis Treatment From Roivant - Roivant Sciences (NASDAQ:ROIV)

Roivant Sciences Ltd (NASDAQ:ROIV) on Thursday secured U.S. Food and Drug Administration approval for LISRAYA (brepocitinib) 30 mg, a once-daily oral medication for adults living with dermatomyositis.

The regulatory decision brings the first and only targeted treatment to market for this rare systemic autoimmune disorder.

Physicians can prescribe the therapy as a standalone option or alongside existing non-targeted therapies, without restrictions regarding prior treatment history or baseline disease severity.

FDA Clearance Expands Dermatomyositis Treatment Options

Dermatomyositis causes progressive muscle weakness, chronic steroid reliance, and painful skin lesions sensitive to light and touch.

FDA Clears First Targeted Dermatomyositis Treatment From Roivant - Roivant Sciences (NASDAQ:ROIV)

Other newsrooms on this story

Related reading

FDA approves Lisraya as first oral drug for dermatomyositis

FDA green lights Priovant drug for rare skin disease

Roivant’s road to a potential blockbuster begins with Lisraya FDA approval

FDA approves Roivant therapy for rare autoimmune disease

First Oral Option for Dermatomyositis Gets FDA Green Light

Priovant pushes ex-Pfizer asset across FDA finish line in rare skin and muscle…